Print

Comparing Three Drugs as Late-Stage Treatment for Individuals with Metastatic Colorectal Cancer

https://www.facingourrisk.org/research-clinical-trials/study/246/comparing-the-drugs-opdualag-and-stivarga-as-late-stage-treatment-for-individuals-with-metastatic-colorectal-cancer

Clinicaltrials.gov identifier:
NCT05328908 (https://clinicaltrials.gov/show/NCT05328908)

Treatment
treatment study for people with metastatic colorectal cancer

Study Contact Information:

For additional information, please contact:

BMS Study Connect Contact Center by phone at (855) 907-3286

or by email at [email protected]. The first line of the email must contain NCT05328908 and the Site #

 


About the Study

This study is being done to look at how well a combination of three drugs works for the treatment of metastatic colorectal cancer in patients who have had their cancer come back or get worse after treatment. The study is open to people who have had at least one, but no more than four courses of treatment in the metastatic setting. 

What the Study Entails

Participants will be randomly selected to participate in either group and they will know which treatment they are receiving.

This study has two groups:

Study Sites

Arkansas

California

Connecticut

Florida

Georgia

Idaho

Indiana

Massachusetts

Michigan

New Jersey

North Carolina

Ohio

Pennsylvania

South Carolina

South Dakota

Tennessee

Texas

Virginia

Wisconsin

 

 

 


This Study is Open To:

Patients 18 years or older who:

 

This Study is Not Open To:

Patients who:

Other exclusion criteria can be found on clinicaltrials.gov

 


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.